Pharmacopoeial impurityGadoteridol USP Related Compound ACat. No. P-G007-005CAS 120041-08-9Family · Pharmaceutical analytical standards
Gadoteridol
A gadolinium-based MRI contrast agent, held in a ring-shaped (macrocyclic) structure that forms a neutral complex. Approved in the United States in 1992, it is used mainly for imaging the central nervous system. This family brings together pharmacopoeial impurities and other impurities.
Did you know?Gadolinium owes its name to the mineral gadolinite, named after Finnish chemist Johan Gadolin, who in 1794 discovered yttrium in a mineral from the Swedish quarry of Ytterby.
Pharmacopoeial impurityGadoteridol USP Related Compound ACat. No. P-G007-005CAS 120041-08-9
ImpurityGadoteridol Impurity ECat. No. P-G007-016CAS 229312-33-8
ImpurityGadoteridol Impurity 8Cat. No. P-G007-018CAS 138884-13-6
ImpurityEcaneCat. No. P-G007-030CAS 148407-91-4
ImpurityGadolinium(III) Acetate HydrateCat. No. P-G007-041CAS 100587-93-7
ImpurityGadoteric AcidCat. No. P-G007-042CAS 72573-82-1
ImpurityGadoteridol Impurity 13Cat. No. P-G007-043
ImpurityGadoteridol Impurity 14Cat. No. P-G007-044
ImpurityGadoteridol Impurity 15Cat. No. P-G007-045
ImpurityGadoteridol Impurity 16Cat. No. P-G007-046
ImpurityGadoteridol Related Compound CCat. No. P-G007-047CAS 220182-19-4
Impurityp-SCN-Bn-DOTACat. No. P-G007-049CAS 127985-74-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.